YD BIO LTD
YDESNASDAQ🏆 #3151 by market capUS Equity
$5.87▼ $0.47 (−7.41%)
Market closed · at closeTrack YDES
Get earnings, price moves & breaking news on Telegram
24h▼ 7.4%
7d▲ 21.3%
14d▼ 2.9%
30d▼ 22.0%
ytd▼ 50.6%
1y▼ 47.5%
🏦Market Cap
$416M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $5.87 – $6.40
- 52-Week Range
- $1.70 – $17.37
- Volume (shares)
- 1,135
- Avg Volume (shares)
- —
- Shares Outstanding
- 70.8M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $596,817
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.03
- Dividend Yield
- —
- Dilution (1yr)
- −15.5%
YD BIO LTD
YDESFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$597K▲ +16.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-7.1%▼ −123.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▲ +260.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$8M▲ +69.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.4M▼ −15.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▲ +$3M YoY
StockOtter · stockotter.spaceAbout YD BIO LTD
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.